Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ISABR Study
- 27 Aug 2024 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
- 27 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 06 Jul 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.